« Return to News | R&D Trends

AstraZeneca, Tufts collaborate on neuroscience research

Thursday, July 18, 2013 09:00 AM

AstraZeneca, Tufts University's School of Medicine and Sackler School of Graduate Biomedical Sciences are collaborating to establish a team of postdoctoral researchers who will work to advance understanding of diseases and disorders of the brain, including Alzheimer's disease, Parkinson's disease, neurodevelopmental and autism spectrum disorders. As part of a three-year agreement, the new team will conduct laboratory research into biological targets of interest in neuroscience.

Stephen Moss, Ph.D., professor of neuroscience at Tufts, will lead the team to explore neurological pathways implicated in brain disease. Moss, an expert in synaptic inhibition, a determinant of neuronal excitability and behavior, will serve as principal investigator and oversee the research, along with John Dunlop and Nick Brandon from AstraZeneca. "This collaboration offers an opportunity to translate basic science findings into new treatments for a range of unmet clinical needs," said Moss.

The group's research will complement the work of the AstraZeneca Neuroscience Innovative Medicines Unit, a small team that advances neuroscience discovery research and early development exclusively via external partners in biotech, CROs, pharma and academia.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.